Analysis of the Efficacy of the Lidocaine Patch 5% in the Treatment of Neuropathic Pain: Our Feedback

P. Hernández-Puiggròs, R. Pélaez, A. Morell, A. Yañez, J. L. Aguilar

Fundació d’Investigació Sanitària Illes Balears (FISIB), Palma de Mallorca, Spain.
Hospital Son Llàtzer, Palma de Mallorca, Spain.

DOI: 10.4236/pst.2014.22015                

Abstract

Objective: the objective of this study was to evaluate the efficacy of the lidocaine patch 5% in different types of neuropathic pain. Methods: a prospective, longitudinal, observational study on a sample of 16 patients who consulted for neuropathic pain. A lidocaine patch 5% was applied to the painful area and as primary endpoint, the severity of the pain was studied using the Verbal Numeric Rating Scale (VNRS). Secondary quality of life-related endpoints were sleep during the night, mood and patient global impression of the treatment. Results: demographic data: 62.5% female and 37.5% male; mean age 55.31 ± 13.9 years; time since onset of the pain 8.4 months; and classified into 4 diagnosis groups: post-herpetic neuralgia 18.8%; complex regional pain syndrome 25%; surgical wound 50%; and others 6.3%. There was a reduction of more than 2 points in pain on the VNRS (median 6.5 to 3.5; p = 0.001), an improvement in sleep during the night, mood and relief (p < 0.05), less use of analgesics, no complications and over 30% of subjects reported improvement of over 50%. Conclusions: The lidocaine patch 5% could be a useful tool for the control of neuropathic pain, not only for post-herpetic neuralgia, and it has a good safety and tolerability profile.

Keywords

Chronic Pain, Neuropathic Pain, Lidocaine Patch

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Breivik, H., et al. (2006) Survey of Chronic Pain in Europe: Prevalence, Impact on Daily Life, and Treatment. European Journal of Pain, 10, 287-333. http://dx.doi.org/10.1016/j.ejpain.2005.06.009
[2]	Elliott, A., et al. (2002) The Course of Chronic Pain in the Community: Results of a 4-Year Follow-Up Study. Pain, 99, 299-307. http://dx.doi.org/10.1016/S0304-3959(02)00138-0
[3]	Smith, B., et al. (2007) Epidemiology of Chronic Pain, from the Laboratory to the Bus Stop: Time to Add Understanding of Biological Mechanism to the Study of Risk Factors in Population-Based Research. Pain, 127, 5-10. http://dx.doi.org/10.1016/j.pain.2006.11.001
[4]	Torrance, N., et al. (2006) The Epidemiology of Chronic Pain of Predominantly Neuropathic Origin: Results from a General Population Survey. Journal of Pain, 7, 281-289. http://dx.doi.org/10.1016/j.jpain.2005.11.008
[5]	Irving, G., et al. (2012) Capsaicin 8% Dermal Patch, Administered alone or in Combination with Systemic Neuropathic Pain Medications, Reduces Pain in Patients with Post-Herpetic Neuralgia. The Clinical Journal of Pain, 28, 101-107. http://dx.doi.org/10.1097/AJP.0b013e318227403d
[6]	Gilron, et al. (2005) Combination Pharmacotherapy for Neuropathic Pain: Current Evidence and Future Directions. Expert Review of Neurotherapeutics, 5, 823-830. http://dx.doi.org/10.1586/14737175.5.6.823
[7]	Sandkühler, J. (2009) Models and Mechanisms of Hyperalgesia and Allodynia. Physiological Reviews, 89, 707-758. http://dx.doi.org/10.1152/physrev.00025.2008
[8]	Maihofner, C., et al. (2006) Functional Imaging of Allodynia in Complex Regional Pain Syndrome. Neurology, 66, 711-717. http://dx.doi.org/10.1212/01.wnl.0000200961.49114.39
[9]	Maihofner, C., et al. (2003) Cortical Processing of Brush-Evoked Allodynia. Neuroreport, 14, 785-789. http://dx.doi.org/10.1097/00001756-200305060-00002
[10]	Volpi, A., et al. (2005) Current Management of Herpes Zoster: the European View. American Journal of Clinical Dermatology, 6, 317-325. http://dx.doi.org/10.2165/00128071-200506050-00005
[11]	Johnson, R.W., et al. (2008) Herpes Zoster and Postherpetic Neuralgia: Optimizing Management in the Elderly Patient. Drug Aging, 25, 991-1006. http://dx.doi.org/10.2165/0002512-200825120-00002
[12]	Baron, R., et al. (2009) 5% Lidocaine Medicated Plaster versus Pregabalin in Post-Herpetic Neuralgia and Diabetic Poluneuropathy: An Open-Label, Non-Inferiority Two Stage RCT Study. Current Medical Research and Opinion, 25, 1663-1676. http://dx.doi.org/10.1185/03007990903047880
[13]	Geha, P.Y., et al. (2007) Brain Activity for Spontaneous Pain of Postherpetic Neuralgia and Its Modulation by Lidocaine Patch Therapy. Pain, 128, 88-100. http://dx.doi.org/10.1016/j.pain.2006.09.014
[14]	Nalamachu, S., et al. (2013) Influence of Anatomic Location of Lidocaine Patch 5% on Effectiveness and Tolerability for Postherpetic Neuralgia. Patient Preference and Adherence, 7, 551-557.
[15]	Wolff, R.F., et al. (2011) REVIEW ARTICLE: 5% Lidocaine-Medicated Plaster vs Other Relevant Interventions and Placebo for Post-Herpetic Neuralgia: A Systematic Review. Acta Neurologica Scandinavica, 123, 295-309. http://dx.doi.org/10.1111/j.1600-0404.2010.01433.x
[16]	Mick, G., et al. (2012) Topical Pain Management with the 5% Lidocaine Medicated Plaster—A Review. Current Medical Research and Opinion, 28, 937-951. http://dx.doi.org/10.1185/03007995.2012.690339
[17]	Perkins, F.M., et al. (2000) Chronic Pain as an Outcome of Surgery. A Review of Predictive Factors. Anesthesiology, 93, 1123-1133. http://dx.doi.org/10.1097/00000542-200010000-00038
[18]	Woolf, C., et al. (2011) Central Sensitization: Implications for the Diagnosis and Treatment of Pain. Pain, 152, 2-15. http://dx.doi.org/10.1016/j.pain.2010.09.030
[19]	Baron, R., et al. (2010) Neuropathic Pain: Diagnosis, Pathophysiological Mechanisms and Treatment. The Lancet Neurology, 9, 807-819. http://dx.doi.org/10.1016/S1474-4422(10)70143-5
[20]	(1978) The Gate Control Theory of Pain (No Authors Listed). British Medical Journal, 2, 586-587. http://dx.doi.org/10.1136/bmj.2.6137.586-a
[21]	Moayedi, et al. (2013) Theories of Pain: From Specificity to Gate Control. Journal of Neurophysiology, 109, 5-12. http://dx.doi.org/10.1152/jn.00457.2012